Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Clinical stage drug development company Telik has reported a net loss of $1.88m, or $0.78 per share, for the third quarter ended 30 September 2012 compared to a net loss of $2.85m, or $1.58 per share, for the third quarter ended 30 September 2011.
Subscribe to our email newsletter
Loss from operations for third quarter of 2012 was $1.88m compared to loss from operations of $2.85m for the third quarter of 2011.
The company reported a net loss of $6.20m, or $3.07 per share, for the nine months ended 30 September 2012 compared to a net loss of $9.52m, or $5.30 per share, for the nine months ended 30 September 2011.
Loss from operations of $6.21m was reported for the first nine months of 2012 compared to loss from operations of $9.55m for the first nine months of 2011.